Monday, January 6, 2014

The Motley Fool: Covidien No Longer Sneaking Up on the Market

One of the most enjoyable experiences for an investor is to find a stock before Wall Street catches on to the company's quality and then hold it throughout that awakening and revaluation processing. The last two years have been good ones for Covidien (NYSE: COV  ) shareholders as this underrated med-tech player got its due. Now the question is what comes next.

Covidien has an enviable hold on its key markets, with a #1 or #2 position in most of its segments, despite competing with some major rivals like Johnson & Johnson (NYSE: JNJ  ) , Bard (NYSE: BCR  ) , Masimo (NASDAQ: MASI  ) , Stryker (NYSE: SYK  ) , and Abbott (NYSE: ABT  ) . Although I believe Covidien will continue a long run of operational success, I'm not nearly so certain that investors should expect another year of 20%-plus returns.

Read the full article here:
Covidien No Longer Sneaking Up on the Market

No comments: